However, to date, only one Food and Drug Administration (FDA)-approved gene therapy is available for collagen disorders, which targets COL7A1 for the treatment of dystrophic epidermolysis bullosa [26]. This evidence concerns the gene COL7A1 and Dystrophic epidermolysis bullosa.